The pharmaceutical industry has been traditionally slow in embracing new technologies, but Divi’s Laboratories is showing the way forward. Recently, this Hyderabad-based firm zeroed in on Juniper ...

Divi’s Labs (DIVI), in addition to having a robust base business, is enhancing its product offerings in the generic API space – at least sixteen molecules are under various phases of development and ...

HYDERABAD, Feb 3 (Reuters) - India's Divi's Laboratories (DIVI.NS), opens new tab reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses ...

Divi's Laboratories, India's largest API (Active Pharmaceutical Ingredient) manufacturer, sits amid a changing landscape within the global pharmaceutical universe. The growth levers for Divi’s are ...

Nov 7 (Reuters) - Indian drugmaker Divi's Laboratories (DIVI.NS), opens new tab reported second-quarter profit above analysts' estimates on Friday, helped by its business that focuses on customised ...

Divi's Labs reported its Q1 results on August 3. Pharma company Divi's Laboratories announced plans to foray into peptide fragment molecules, advancing from the peptide building blocks it currently ...

Divi’s Laboratories came under pressure on Monday following a key negative development around a blockbuster cardiac drug. SEBI-registered analyst Prabhat Mittal said Divi’s made an intraday low of ...

Murali Krishna Divi Chairman and managing director, Divis Laboratories Age: 63 Rank in the Rich List: 45 Net Worth: $2.03 billion The Big Challenge Faced in the Last Year: Managing growth in an ...